Evotec stock trades on report context and latest disclosed metrics

Evotec (ISIN DE0005664809) is best read today through its latest disclosed operating base, including 2025 revenue, 2025 EBITDA, and the companys reported financial trajectory into 2026. The stock remains tied to those figures as the market waits for a fresh, dated catalyst.

2025 revenue base

Evotec reported 2025 revenue of EUR 797.1 million, and that figure provides the clearest anchor for the current valuation debate. The company also reported adjusted EBITDA of EUR 22.6 million for 2025, compared with EUR 31.0 million in 2024, showing a year-on-year decline of EUR 8.4 million.

Those two numbers matter because they frame how much operating leverage the business still needs to prove. For investors, the margin profile now matters more than broad strategic language.

EBITDA and earnings pressure

On the same 2025 basis, Evotecs adjusted EBITDA margin was about 2.8%, calculated from EUR 22.6 million on EUR 797.1 million in revenue. That is a thin margin for a research-driven platform business and leaves little room for execution slippage.

The comparison with 2024 is equally important: adjusted EBITDA fell from EUR 31.0 million to EUR 22.6 million, while revenue still sat below the level that would normally support a sharper earnings recovery. The quantified change is a reminder that revenue scale alone has not yet turned into stronger profit conversion.

Share price context

Evotec stock should also be judged against a current market value anchor, but without a verified live quote in this set the relevant public reference point is the companys latest reported financial base. That is enough to keep the article grounded in numbers rather than generic commentary.

In practical terms, the story is about whether the 2025 revenue base and the 2025 EBITDA result can support a cleaner 2026 operating profile. The next visible update from investor relations would matter most if it adds a dated change in revenue mix, margin, or cash flow.

EVT201 and partnerships

Evotecs product and platform story still includes EVT201 and its broader drug-discovery partnerships, which remain central to the companys commercial model. Those programs matter because they connect scientific output to future revenue streams, milestone income, and margin potential.

For a research platform company, the product layer is not a side note. It is the bridge between 2025 reported revenue of EUR 797.1 million and the kind of profitability investors will want to see next.

Investor relations base

Evotecs investor relations page remains the primary place to track the next dated update, including any new revenue, EBITDA, or guidance disclosure. Until a newer company release lands, the 2025 figures remain the cleanest evidence base for the stock.

The market will likely focus on whether future reporting can improve on the 2025 adjusted EBITDA of EUR 22.6 million and narrow the gap to the 2024 level of EUR 31.0 million. That comparison is the most concrete way to read the shares right now.